Efalizumab (Raptiva) for the treatment of moderate to severe chronic plaque psoriasis
In Feb 2009 the European Medicines Agency suspended the marketing authorisation for this product across the EU due to safety concerns.
The SMC Advice has been removed from the website.
- Medicine name:
- Efalizumab (Raptiva®)
- SMC ID:
- Moderate to severe chronic plaque psoriasis
- Pharmaceutical company
- Serono Ltd
- BNF chapter
- Submission type
- Date advice published:
- 10 January 2005
In February 2009 the European Medicines Agency completed a review of efalizumab (Raptiva) after concerns about its safety .The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of efalizumab do not outweigh its risks and that the Marketing Authorisation should be suspended across the EU.